SCHEMBL24780239

SCHEMBL24780239

CCc1ccc(-n2cnc(C)c2)nc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.42
CYP2D6 P10635 2/20 0.42
CYP3A4 P08684 1/20 0.42
CYP19A1 P11511 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
CYP2E1 P05181 1/20 0.41
CYP2A6 P11509 1/20 0.41
KCNJ1 P48048 3/20 0.41
PSEN1 P49768 4/20 0.40
PSEN2 P49810 4/20 0.40
APH1B Q8WW43 4/20 0.40
NCSTN Q92542 4/20 0.40
APH1A Q96BI3 4/20 0.40
PSENEN Q9NZ42 4/20 0.40
KDM4E B2RXH2 2/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
HRH3 Q9Y5N1 1/20 0.36
SYK P43405 1/20 0.35
SCD O00767 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25560652 0.85 KCNJ1 (0.41) CYP1A2CYP2D6CYP3A4CYP19A1CYP2C9
SCHEMBL24135102 0.85 EGLN2 (0.44) CYP1A2CYP2D6CYP3A4CYP19A1CYP2C9
SCHEMBL25442822 0.82 L3MBTL1 (0.35) CYP1A2CYP2D6KDM4EL3MBTL1HRH3
SCHEMBL6127814 0.79 CYP2E1 (0.46) CYP1A2CYP2D6CYP3A4CYP19A1CYP2C9
SCHEMBL10280811 0.77 CYP1A2 (0.61) CYP1A2CYP2D6CYP3A4CYP19A1CYP2C9
SCHEMBL9925940 0.76 CYP1A2 (0.41) CYP1A2CYP2D6CYP3A4CYP19A1CYP2C9
SCHEMBL28674063 0.76 PSEN1 (0.48) CYP1A2CYP2D6CYP3A4CYP19A1CYP2C9
SCHEMBL22199018 0.76 CYP2E1 (0.44) CYP1A2CYP2D6CYP3A4CYP19A1CYP2C9
SCHEMBL11962606 0.76 CYP2E1 (0.44) CYP1A2CYP2D6CYP3A4CYP19A1CYP2C9
SCHEMBL30445326 0.75 KCNJ1 (0.49) CYP1A2CYP2D6CYP3A4CYP19A1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220396631-A1 TRISPECIFIC BINDING MOLECULES AGAINST BCMA AND USES THEREOF NOVARTIS AG (CH) 2022-12-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220396631-A1 TRISPECIFIC BINDING MOLECULES AGAINST BCMA AND USES THEREOF CD2, CD2BP2, CD22 CYP1A2 4664/4885CYP2D6 2632/4885CYP3A4 3551/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.